Topics:
Genitourinary Cancers • Medical Oncology
How do you approach patients with biochemical relapse of high-risk prostate cancer, with PSA doubling time less than 6 months?
Pt previously treated with radical prostatectomy and adjuvant radiotherapy.
If recommending therapy, what is the role of concurrent abiraterone + ADT?
The STAMPEDE study in NEJM July 2017 included some patients who were previously treated with radical surgery or radiotherapy and were relapsing with high-risk features (in men no longer receiving therapy, a PSA level >4 ng per milliliter with a doubling time of <6 months, a PSA level >20 ng per milliliter, nodal or metastatic relapse, or <12 months of total ADT with an interval of >12 months without treatment)
Answer from: Medical Oncologist at Academic Institution
This is a very thoughtful question. The assumption is that the patient has no evidence on conventional imaging by (CT/Bone scan) and BCR with rapidly doubling PSA after both prostatectomy and adjuvant XRT. The biology of these patients remains concerning and although STAMPEDE would include these typ...
Sign in or Register to read more